Stay updated with breaking news from Ederal circuit. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
WASHINGTON (Reuters) -Apple cannot sell two flagship Apple Watch models in the U.S. as the iPhone maker fights a legal battle over patents covering a blood oxygen measurement feature, an appeals court ruled on Wednesday. The legal fight could take a year and analysts expect Apple to disable the disputed feature in the meantime to comply with the ban and keep the watch on sale. Apple shares were down 0.5% to $182.65 after the U.S. Court of Appeals for the Federal Circuit ruled the company can no longer sell Series 9 and Ultra 2 Apple Watches with the blood oxygen feature at the center of a wide-ranging legal battle with medical technology company Masimo.
Tech company rebuts claims made by ITC and watch rival | Apple criticises ITC's “lack of understanding of its own record” | Masimo CEO Joe Kiani “lacks personal knowledge” says under-fire company.
One of the biggest patent infringement verdicts in the US has been thrown out by the Court of Appeals. WIPR gauges litigators’ reaction to the reversal, includi
NYIPLA and AIPLA urge for a Federal Circuit rehearing in case concerning patent term guarantees and obviousness-type double patenting | Impact of doctrine on pa
Recent developments at the Federal Circuit and the USPTO can inform evolving patent strategy on medical technology. In one case, the Federal Circuit...
The International Trademark Association files amicus brief urging Appeals Court to maintain obviousness test | Design patents have become “front line of defence